Non-eosinophilic asthma in nonsteroidal anti-inflammatory drug exacerbated respiratory disease.
aspirin hypersensitivity
cluster analysis
inflammatory phenotypes
non-eosinophilic asthma
Journal
Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
12
02
2023
received:
06
12
2022
accepted:
24
02
2023
medline:
29
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
ppublish
Résumé
The cellular inflammatory pattern of nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is heterogeneous. However, data on the heterogeneity of non-eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N-ERD patients based on clinical data and eicosanoid biomarkers we aimed to identify NEA endotypes potentially guiding clinical management. Induced sputum was collected from patients with N-ERD. Sixty six patients (49.6% of 133 N-ERD) with NEA were included in the hierarchical cluster analysis based on clinical and laboratory data. The quality of clustering was evaluated using internal cluster validation with different indices and a practical decision tree was proposed to simplify stratification of patients. The most frequent NEA pattern was paucigranulocytic (PGA; 75.8%), remaining was neutrophilic asthma (NA; 24.2%). Four clusters were identified. Cluster #3 included the highest number of NEA patients (37.9%) with severe asthma and PGA pattern (96.0%). Cluster #1 (24.2%) included severe only asthma, with a higher prevalence of NA (50%). Cluster #2 (25.8%) comprised well-controlled mild or severe asthma (PGA; 76.5%). Cluster #4 contained only 12.1% patients with well-controlled moderate asthma (PGA; 62.5%). Sputum prostaglandin D Among identified four NEA subtypes, clusters #3 and #1 represented N-ERD patients with severe asthma but a different inflammatory signatures. All the clusters were discriminated by sputum PGD
Sections du résumé
BACKGROUND
BACKGROUND
The cellular inflammatory pattern of nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is heterogeneous. However, data on the heterogeneity of non-eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N-ERD patients based on clinical data and eicosanoid biomarkers we aimed to identify NEA endotypes potentially guiding clinical management.
METHODS
METHODS
Induced sputum was collected from patients with N-ERD. Sixty six patients (49.6% of 133 N-ERD) with NEA were included in the hierarchical cluster analysis based on clinical and laboratory data. The quality of clustering was evaluated using internal cluster validation with different indices and a practical decision tree was proposed to simplify stratification of patients.
RESULTS
RESULTS
The most frequent NEA pattern was paucigranulocytic (PGA; 75.8%), remaining was neutrophilic asthma (NA; 24.2%). Four clusters were identified. Cluster #3 included the highest number of NEA patients (37.9%) with severe asthma and PGA pattern (96.0%). Cluster #1 (24.2%) included severe only asthma, with a higher prevalence of NA (50%). Cluster #2 (25.8%) comprised well-controlled mild or severe asthma (PGA; 76.5%). Cluster #4 contained only 12.1% patients with well-controlled moderate asthma (PGA; 62.5%). Sputum prostaglandin D
CONCLUSIONS
CONCLUSIONS
Among identified four NEA subtypes, clusters #3 and #1 represented N-ERD patients with severe asthma but a different inflammatory signatures. All the clusters were discriminated by sputum PGD
Identifiants
pubmed: 36973957
doi: 10.1002/clt2.12235
pmc: PMC10009799
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12235Subventions
Organisme : Narodowe Centrum Nauki
ID : UMO-2015/19/B/NZ5/00096
Organisme : Narodowe Centrum Nauki
ID : UMO-2018/31/B/NZ5/0080
Informations de copyright
© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Références
Bioorg Med Chem Lett. 2012 Feb 15;22(4):1686-9
pubmed: 22264478
Blood. 2012 Apr 19;119(16):3790-8
pubmed: 22262771
Am J Respir Crit Care Med. 2015 Sep 15;192(6):682-94
pubmed: 26067893
Allergy Asthma Proc. 2021 Nov 1;42(6):530-536
pubmed: 34871161
Clin Exp Allergy. 2015 Dec;45(12):1779-89
pubmed: 26449970
Clin Exp Allergy. 2021 Aug;51(8):1046-1056
pubmed: 33905579
Can Respir J. 2011 May-Jun;18(3):144-8
pubmed: 21766077
Respir Med. 2019 Jun;152:51-59
pubmed: 31128610
N Engl J Med. 2017 Sep 7;377(10):936-946
pubmed: 28877011
Eur Respir J. 2021 Feb 4;57(2):
pubmed: 33008937
J Allergy Clin Immunol. 2013 Oct;132(4):856-65.e1-3
pubmed: 23806637
J Allergy Clin Immunol. 2021 Feb;147(2):587-599
pubmed: 32540397
J Allergy Clin Immunol. 2017 Jul;140(1):101-108.e3
pubmed: 28279492
Allergy. 2020 Jul;75(7):1649-1658
pubmed: 32012310
N Engl J Med. 2018 Sep 13;379(11):1060-1070
pubmed: 30207919
Allergy. 2020 Apr;75(4):831-840
pubmed: 31803947
J Allergy Clin Immunol. 2016 Mar;137(3):833-43
pubmed: 26792210
J Allergy Clin Immunol. 2021 Aug;148(2):439-449.e5
pubmed: 33819512
Respirology. 2006 Jan;11(1):54-61
pubmed: 16423202
Allergy. 2019 May;74(5):922-932
pubmed: 30446997
N Engl J Med. 2021 May 13;384(19):1800-1809
pubmed: 33979488
Allergy. 2020 Feb;75(2):311-325
pubmed: 31309578
Am J Respir Crit Care Med. 2009 Sep 1;180(5):388-95
pubmed: 19483109
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1133-1141
pubmed: 33065369
J Allergy Clin Immunol. 2022 Apr;149(4):1286-1295
pubmed: 34543652
Am J Respir Crit Care Med. 2012 Mar 15;185(6):612-9
pubmed: 22268133
Allergy. 2021 Jan;76(1):114-130
pubmed: 32279330
Allergy. 2017 Apr;72(4):616-626
pubmed: 27805264
J Allergy Clin Immunol. 2021 Apr;147(4):1318-1328.e5
pubmed: 33189729
J Allergy Clin Immunol. 2021 Feb;147(2):501-503
pubmed: 33358894
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2344-2355
pubmed: 33482419
Allergy. 2019 Sep;74(9):1649-1659
pubmed: 30865306
J Asthma Allergy. 2018 Oct 29;11:267-281
pubmed: 30464537
Allergy. 2021 Jan;76(1):14-44
pubmed: 32484954
BMC Pulm Med. 2016 Apr 05;16:46
pubmed: 27044366
Eur Respir J Suppl. 2002 Sep;37:1s-2s
pubmed: 12361359
Allergy. 2020 Mar;75(3):713-716
pubmed: 31583712